

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Protext Mobility, Inc.
258 South Military Trail
Deerfield Beach, FL. 33442
617-504-3635
SIC 2833

Annual Report
For the Period Ending: December 31, 2021
(the "Reporting Period")

As of December 31, 2021, the number of shares outstanding of our Common Stock was:

7,831,465,506

As of September 30, 2021, the number of shares outstanding of our Common Stock was:

7,388,175,006

As of December 31, 2020, the number of shares outstanding of our Common Stock was:

4,874,316,008

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: ☐ No: ☒

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Protext Mobility- December 2010 - present
EchoMetrix- May, 2009- December, 2010
SearchHelp, Inc.- September, 2001 -May, 2009

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

<u>Name</u>	<u>State of incorporation</u>	<u>Standing</u>
Protext Mobility	Delaware	Active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

258 South Military Trail
Deerfield Beach, FL. 33442

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

None

2) Security Information

Trading symbol:	<u>TXTM</u>
Exact title and class of securities outstanding:	<u>Common Stock</u>
CUSIP:	<u>74371E204</u>
Par or stated value:	<u>\$0.00001</u>
Total shares authorized:	<u>10,000,000,000</u> as of date: <u>December 31, 2021</u>
Total shares outstanding:	<u>7,831,465,506</u> as of date: <u>December 31, 2021</u>
Number of shares in the Public Float ² :	<u>7,070,818,182</u> as of date: <u>December 31, 2021</u>
Total number of shareholders of record:	<u>42</u> as of date: <u>December 31, 2021</u>

All additional class(es) of publicly traded securities (if any): None

Trading symbol:	<u>N/A</u>
Exact title and class of securities outstanding:	<u>N/A</u>
CUSIP:	<u>N/A</u>
Par or stated value:	<u>N/A</u>

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

Total shares authorized: N/A as of date: N/A
Total shares outstanding: N/A as of date: N/A

Transfer Agent

Name: Clear Trust, LLC
Phone: 813-235-4490
Email: inbox@cleartrusttransfer.com
Address: 16540 Pointe Village Dr.
Suite 205
Lutz, FL 33558

Is the Transfer Agent registered under the Exchange Act?³ Yes: ☒ No: ☐

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

[Table continues on Next Page]

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12/31/2019</u> Common: 4,574,316,008 Preferred: <u>3,355,126</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
8/3/2020	Issuance	300,000,000	Common		No	Bruce Lewis	Note conversion	Unrestricted	<u>4(a)1</u>
02/11/2021	Issuance	461,330,466	Common		No	<u>Union Capital, LLC</u> <u>Yakov Borenstein</u>	Note conversion	Unrestricted	<u>4(a)1</u>
02/24/2021	Issuance	468,030,000	Common		No	<u>BB Winks LLC</u> <u>Craig Fisher</u>	Note conversion	Unrestricted	<u>4(a)1</u>
4/28/2021	Issuance	271,867,306	Common		Yes	<u>Union Capital, LLC</u> <u>Yakov Borenstein</u>	Note conversion	Unrestricted	<u>4(a)1</u>
06/01/2021	Issuance	460,000,000	Common		Yes	<u>Bruce Lewis</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
6/22/21	Issuance	12,523,985	Common		Yes	<u>Gel Properties LLC</u> <u>Arveh Goldstein</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
6/23/21	Issuance	308,276,015	Common		Yes	<u>Gel Properties LLC</u> <u>Arveh Goldstein</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
6/22/21	Issuance	70,000,000	Common		Yes	<u>Gel Properties LLC</u> <u>Arveh Goldstein</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
6/22/21	Issuance	9,200,000	Common		Yes	<u>Gel Properties LLC</u> <u>Arveh Goldstein</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
9/23/21	Issuance	145,370,766	Common		Yes	<u>Lance Quartieri</u>	Note Conversion	Unrestricted	<u>4(a)1</u>
9/20/21	Issuance	307,258,460	Common		Yes	<u>Richard Grossfeld</u>	Pref A Conversion	Unrestricted	<u>4(a)1</u>
9/20/21	Cancellation	22,151	Pref A		N/A	<u>Richard Grossfeld</u>	Conversion to common	N/A	<u>N/A</u>
10/15/21	Cancellation	46,052	Pref B		N/A	<u>Jamie Safier</u>	Conversion to Pref A	N/A	<u>N/A</u>
10/15/21	Issuance	30,000	Pref A		N/A	<u>Jamie Safier</u>	Conversion of Pref B	N/A	<u>N/A</u>
10/26/21	Cancellation	30,000	Pref A		N/A	<u>Jamie Safier</u>	Conversion to common	N/A	<u>N/A</u>
10/26/21	Issuance	443,290,500	Common		N/A	<u>Jamie Safier</u>	Conversion of Pref A	Unrestricted	<u>4(a)1</u>
Shares Outstanding on Date of This Report: Date <u>12/31/2021</u> <u>Ending Balance</u> Common: <u>7,831,465,506</u> <u>Ending Balance:</u> Preferred: <u>3,286,923</u>									

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended September 30, 2020, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2018 through September 30, 2020 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☐

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
<u>12/30/11</u>	<u>\$39,052</u>	<u>\$77,000</u>		<u>12/30/12</u>	lesser of (60%) of the 5day VWAP or last lowest conversion price in the 120-day period prior to date of conversion (no conversion below floor of .0001)	<u>Bruce Lewis</u>	<u>Loan</u>
<u>6/25/18</u>	<u>\$10,171</u>	<u>\$22,000</u>	<u>1,760</u>	<u>6/25/19</u>	<u>Fixed price .0001</u>	<u>BB Winks, LLC</u> <u>Craig Fischer</u>	<u>Loan</u>

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: John D. Patterson
Title: CPA
Relationship to Issuer: Accountant

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
D. Statement of income;
E. Statement of cash flows;
F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
G. Financial notes; and
H. Audit letter, if audited

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

The financial statements for the year ended December 31, 2021 are attached hereto.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The Company focuses on the development of pharmaceutical applications for botanical drugs and has the worldwide exclusive license to develop Phytofare® in botanical drug applications. Phytofare® is a highly bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have more than ten-times greater bioavailability over generic extract.

B. Please list any subsidiaries, parents, or affiliated companies.

EchoMetrix
Plandai Biotechnology
Cannabis Biosciences, Inc.

C. Describe the issuers' principal products or services.

The Company focuses on the development of pharmaceutical applications for botanical drugs and has the worldwide exclusive license to develop Phytofare® in botanical drug applications. Phytofare® is a highly bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have more than ten-times greater bioavailability over generic extract.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The issuer utilizes space provided by its CEO at no cost.

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>McCallum Trust/ Baylis Duffied</u>	<u>CEO of Plandai Biotechnology</u>	<u>17 Hanover Square, London, England</u>	<u>0</u>	<u>Series D Preferred</u>	<u>0</u>	On May 1, 2020, Plandai Biotechnology, Inc., the entity from which Plandai Biotechnology South Africa was acquired, agreed to return and cancel all Series D shares due to breach of contract.
Steve Berman	<u>Holder of more than 5% of a class of securities</u>	New York, NY	2,675,000	Series C Preferred	100%	<u>Voting stock only, converts to 535 million votes equal to less than 10%. Preferred holder is not a control person or affiliate and has no conversion rights</u>
David Lewis	<u>Director</u>	<u>Deerfield Beach, FL</u>	49,500	Series A Preferred	72%	

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

No

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

No

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

No

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

N/A

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Jonathan Leinwand
Firm: Jonathan D. Leinwand, P.A.
Address 1: 18305 Biscayne Blvd, Suite 200
Address 2: Aventura, FL 33180
Phone: (954) 903-7856
Email: jonathan@jdlpa.com

Accountant or Auditor

Name: John D. Patterson, CPA
Firm: Patterson CPA's, LLC
Address 1: 772 West Shepard Lane, STE 101
Address 2: Farmington, UT, 84025
Phone: 801-451-8886
Email: john@gapcpas.com

Investor Relations

Name:
Firm:
Address 1:
Address 2:
Phone:
Email:

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name:
Firm:
Nature of Services:
Address 1:
Address 2:
Phone:
Email:

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, David Lewis certify that:

1. I have reviewed this Quarterly Disclosure Statement of PROTEXT MOBILITY, INC (aka Protext Pharma, Inc.);
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

4/14/2022 [Date]

/S/ David Lewis [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, David Lewis certify that:

1. I have reviewed this Quarterly Disclosure Statement of PROTEXT MOBILITY, INC (aka Protext Pharma, Inc.);
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

4/14/2022 [Date]

/S/ David Lewis [CFO's Signature]

(Digital Signatures)

Protext Mobility, Inc.
(aka Protext Pharma, Inc.)
OTCPK: TXTM
Financial Statements
December 31, 2021
(Unaudited)

PROTEXT MOBILITY, INC.
(aka Protext Pharma, Inc.)
Balance Sheets as of
(Unaudited)

	December 31, 2021	December 31, 2020
ASSETS		
Cash	\$ -	\$ -
Total Current Assets	-	-
Fixed Assets		
License Agreement	170,000	170,000
Capitalized Software Development	33,395	33,395
Total Fixed Assets	203,395	203,395
TOTAL ASSETS	\$ 203,395	\$ 203,395
LIABILITIES & EQUITY		
Current Liabilities		
Accounts Payable and Accrued Expenses	\$ 632,414	\$ 661,585
Accrued Interest	63,205	217,730
Derivative Liability	108,192	288,650
Accrued Salary	458,604	378,604
Convertible Notes Payable	70,303	302,152
Other Notes Payable	-	-
Total Current Liabilities	1,332,718	1,848,721
Total Liabilities	1,332,718	1,848,721
Equity		
Common Stock, 10,000,000,000 shares par value \$0.0001 authorized, 7,831,465,506 and 4,874,316,008 issued and outstanding,	344,459	48,744
Common Stock Issuable	60,750	60,750
Additional Paid-in Capital	2,214,492	1,851,794
Preferred Stock-Series A 100,000 par value \$0.001 shares authorized, 49,957 and 72,108 shares issued and outstanding	50	72
Preferred Stock-Series B 1,000,000 par value \$0.0001 shares authorized, 457,951 and 504,003 shares issued and outstanding	1	1
Preferred Stock - Series C 9,000,000 par value \$0.001 shares authorized, 2,675,000 issued and outstanding	2,675	2,675
Preferred Stock - Series D 100,000 par value \$0.001 shares authorized, -0- shares issued and outstanding	-	-
Retained Deficit	(3,751,750)	(3,609,362)
Total Equity	(1,129,323)	(1,645,326)
TOTAL LIABILITIES & EQUITY	\$ 203,395	\$ 203,395

PROTEXT MOBILITY, INC.
(aka Protext Pharma, Inc.)
Statements of Income
(Unaudited)

	For the Year Ended	
	December 31, 2021	December 31, 2020
	<u>2021</u>	<u>2020</u>
Expenses		
Payroll	\$ 80,000	\$ 80,000
Consulting	-	-
Professional Services	-	2,000
General and Admin	6,000	-
Total Expense	<u>86,000</u>	<u>82,000</u>
Net Operating Loss	<u>(86,000)</u>	<u>(82,000)</u>
Loss on write down of assets	-	(400,000)
Cancellation of common stock issuable	-	56,000
Cancellation of preferred stock	-	100
Loss on judgement	-	-
Gain on forgiveness of debt	-	-
Interest Expense	(56,288)	(80,132)
Net Loss	<u><u>\$ (142,288)</u></u>	<u><u>\$ (506,032)</u></u>

PROTEXT MOBILITY, INC.

Statements of Equity

(Unaudited)

	Shares Outstanding	Common Stock	Series A Preferred	Series B Preferred	Series C Preferred	Series D Preferred	Paid In Capital	Stock Issuable	Retained Earnings	Total
Balance at December 31, 2018	4,324,316,008	\$ 43,244	\$ 72	\$ 1	\$ 2,675	\$ 100	\$ 1,791,294	\$ 116,750	\$(1,600,039)	354,097
Shares issued on conversion of debt	250,000,000	2,500					27,500			30,000
Net Loss of the Period									(1,503,391)	(1,503,391)
Balance at December 31, 2019	4,574,316,008	45,744	72	1	2,675	100	1,818,794	116,750	(3,103,430)	(1,119,294)
Shares issued on conversion of debt	300,000,000	3,000					33,000			36,000
Stock cancelled						(100)		(56,000)	-	(56,100)
Net Loss of the Period									(506,032)	(506,032)
Balance at December 31, 2020	4,874,316,008	48,744	72	1	2,675	-	1,851,794	60,750	(3,609,462)	(1,645,426)
Common share issued on conversion of preferred stock	750,548,960	75,055	(22)				(75,033)			-
Shares issued on conversion of debt and interest	2,206,600,538	220,660					437,731			658,391
Net Loss of the Period									(142,288)	(142,288)
Balance at December, 2021	7,831,465,506	\$ 344,459	\$ 50	\$ 1	\$ 2,675	\$ -	\$ 2,214,492	\$ 60,750	\$(3,751,750)	\$ (1,129,323)

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements

PROTEXT MOBILITY, INC.
(aka Protext Pharma, Inc)
Statements of Cash Flows
(Unaudited)

	For the Year Ended	
	December 31,	
	2021	2020
	<u> </u>	<u> </u>
Cash Used in Operations:		
Net loss	\$ (142,288)	\$ (506,032)
Gain on cancellation of stock		(56,100)
Loss on write down of assets		400,000
Non-cash Adjustments to operating accounts		
Increase in accrued expenses	6,000	2,000
Increase in accrued interest	56,288	76,432
Increase in accrued salaries	80,000	80,000
Net cash from operating activities	<u> -</u>	<u> (3,700)</u>
Cash Provided from Financing Activities		
Proceeds from convertible debt	<u> -</u>	<u> 3,700</u>
	<u> -</u>	<u> 3,700</u>
Net Change in Cash Flow	-	-
Cash at beginning of period	<u> -</u>	<u> -</u>
Cash at end of period	<u><u> \$ -</u></u>	<u><u> \$ -</u></u>
Supplemental Cash Flow Information:		
Cash Paid for -		
Interst	\$ -	\$ -
Taxes	\$ -	\$ -
Shares issued on conversion of debt and interest	\$ 658,391	\$ 36,000

PROTEXT MOBILITY, INC.
(aka Protext Pharma, Inc.)
Notes to Unaudited Consolidated Financial Statements
December 31, 2021

NOTE 1 - DESCRIPTION OF BUSINESS AND GOING CONCERN

ProText Mobility Inc. (the “Company”) was incorporated in the State of Delaware on September 5, 2001 under the name SearchHelp, Inc. and completed its initial public offering on July 23, 2003. During the fiscal year ended December 31, 2008, the Company acquired 100% of the stock of EchoMetrix, Inc, which then became a wholly owned subsidiary, and in May of 2009 the Company filed a Certificate of Ownership and Merger with the State of Delaware pursuant to which EchoMetrix was merged with and into the Company, and the Company's corporate name was changed to EchoMetrix, Inc. In December 2010, filed a Certificate of Ownership and Merger with the state of Delaware pursuant to which the Company's then wholly owned subsidiary, ProText Mobility, Inc., was merged with and into the Company, and the Company's corporate name was changed to Protext Mobility, Inc.

On December 31, 2016, the Company acquired Plandaí Biotechnology South Africa (Pty) Ltd. (Plandaí), a South African company headquartered in the Mpumalanga province of South Africa through a share exchange agreement, and changed the corporate name to Protext Pharma, Inc. Plandaí was formed in 2014 and focuses on the development of pharmaceutical applications for botanical drugs and has the worldwide exclusive license to develop Phytofare® in botanical drug applications. Phytofare® is a highly bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have ten-times greater bioavailability over generic extract. The Company plans to commence human clinical trials to determine the effectiveness of using Phytofare® catechin complex in regulating insulin levels in Type II Diabetes patients. Under the terms of acquisition, the Company issued 100,000 shares of Series D Preferred Stock in exchange for all of the issued and outstanding shares of Plandaí. The Series D Preferred have the right to convert into 75% of the post-conversion issued and outstanding common stock of the Company. The Series D Preferred have voting rights equal to the number of shares issuable on conversion on all shareholder matters. On May 1, 2020, Plandaí Biotechnology, Inc., the entity from which Plandaí Biotechnology South Africa was acquired, agreed to return and cancel all Series D share due to breach of contract.

As a result of the acquisition of Plandaí, the former shareholders of Plandaí became the control entity, having voting and conversion rights equal to 75%. Plandaí elected to become the successor issuer to the Company for accounting and reporting purposes. Accordingly, the accompanying financial statements represent the results of operations of Plandaí Biotechnology South Africa exclusive of those of ProText Mobility. The balance sheet contains the consolidated assets and liabilities of both entities for all periods presented while the retained deficit is that of Plandaí exclusively. The shares of common stock of ProText Mobility outstanding as of the acquisition date are shown as issued as of the acquisition date while the shares issued to acquire Plandaí are shown as outstanding for all periods presented.

On March 14, 2017, the Company acquired 100% of the capital stock of Cannabis Biosciences, Inc., in exchange for 50,000,000 shares of the Company's restricted common stock. Cannabis Biosciences is engaged in the development of a non-psychoactive, full-profile cannabis extract using the Phytofare® technology for pharmaceutical applications. The operations of Cannabis Biosciences from the date of the acquisition forward have been consolidated in these financial statements. On May 1, 2020, Plandaí Biotechnologies agreed to cancel 40,000,000 shares which were issuance due to breach of contract.

The consolidated financial statements presented have been prepared pursuant to U.S. Generally Accepted Accounting Principles (USGAAP). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America, have been omitted pursuant to accepted rules and regulations for smaller reporting companies, but we believe that the disclosures are adequate to make the information presented not misleading. In the opinion of management, all adjustments, consisting of normal, recurring adjustments and disclosures necessary for a fair presentation of these statements have been included. All intercompany transactions have been eliminated in consolidation.

Going Concern

The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern. To date, the Company has generated minimal revenue and has a history of net losses. These circumstances raise substantial doubt about the Company's ability to continue as a going concern. The unaudited consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management's efforts have been directed towards the development and implementation of a plan to generate sufficient revenues to cover all of its present and future costs and expenses.

If the Company does not generate sufficient revenues from the sales of its products in an amount necessary to meet its cash needs, the Company will need additional financing to continue to operate. There are no assurances that the Company can continue to successfully raise additional financing. If the Company fails to raise additional financing, it might have to file for reorganization under bankruptcy laws to satisfy its outstanding liabilities.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments consisting of a normal and recurring nature considered necessary for a fair presentation have been included.

Use of Estimates

The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses in the reporting period. We regularly evaluate our estimates and assumptions related to the useful life and recoverability of long-lived assets, stock-based compensation and deferred income tax asset valuation allowances. We base our estimates and assumptions on current facts, historical experience and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by us may differ materially and adversely from our estimates. To the extent there are material differences between our estimates and the actual results, our future results of operations will be affected.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with original maturities of three months or less when acquired, to be cash equivalents.

Income Taxes

The Company accounts for income taxes under the provisions issued by the FASB which requires recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company computes tax asset benefits for net operating losses carried forward. The potential benefit of net operating losses has not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

Fair Value of Financial Instruments

Pursuant to ASC No. 820, “Fair Value Measurements and Disclosures”, the Company is required to estimate the fair value of all financial instruments included on its balance sheet as of December 30, 2021 and December 31, 2020. The Company’s financial instruments consist of cash and derivative liabilities. The Company considers the carrying value of such amounts in the financial statements to approximate their fair value due to the short-term nature of these financial instruments.

The Company adopted ASC No. 820-10 (ASC 820-10), Fair Value Measurements. ASC 820-10 relates to financial assets and financial liabilities. ASC 820-10 defines fair value, establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (GAAP), and expands disclosures about fair value measurements. The provisions of this standard apply to other accounting pronouncements that require or permit fair value measurements and are to be applied prospectively with limited exceptions.

ASC 820-10 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. This standard is now the single source in GAAP for the definition of fair value, except for the fair value of leased property as defined in SFAS 13. ASC 820-10 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions, about market participant assumptions, that are developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below:

- Level 1 Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
- Level 2 Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3 Inputs that are both significant to the fair value measurement and unobservable. These inputs rely on management's own assumptions about the assumptions that market participants would use in pricing the asset or liability. (The unobservable inputs are developed based on the best information available in the circumstances and July include the Company's own data.)

The following presents the Company's fair value hierarchy for those assets and liabilities measured at fair value on a non-recurring basis as of December 30, 2021 and December 31, 2020:

December 31, 2021:

	Level 1	Level 2	Level 3	Total
	\$ -	\$ -	\$ -	\$ -
Total	\$ -	\$ -	\$ -	\$ -

December 31, 2020:

	Level 1	Level 2	Level 3	Total
	\$ -	\$ -	\$ -	\$ -
Total	\$ -	\$ -	\$ -	\$ -

Derivative Financial Instruments

Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.

Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.

As of December 31, 2021, the fair value of the embedded derivative instruments was not considered material as all convertible instruments had previously been modified to have fixed-floor conversion features. The derivative liability previously recorded and associated with the convertible notes has not been modified and will be written off as notes are converted or repaid.

Research and Development Costs

Costs incurred in the research and development during the preliminary project stage are expensed as incurred. Costs specifically attributable to clinical trials are capitalized and amortized over the expected life of the product. Prior to 2015, the Company capitalized a total of \$433,395 associated with software development by ProText Mobility. The Company continually evaluates capitalized costs for potential impairment and determined as of December 31, 2020 that the software was materially and permanently impaired. As a result, the Company reduced the value of the asset by \$400,000, which was recorded as a loss in the year ended December 31, 2020.

NOTE 3 - CONVERTIBLE NOTES PAYABLE

In prior years, the Company issued convertible notes payable to various individuals and funds, of which \$155,500 remained issued and outstanding as of December 31, 2020. As of December 31, 2016, the Company had negotiated with most of the convertible debt holders to eliminate all accrued interest and penalties and place a moratorium on future interest payments and conversions for a period of at least six months. Future conversions will not involve any discount off the then-trading price of the common stock. As a result, the derivative liability associated with these notes was deemed immaterial and all discounts and derivative liabilities were eliminated.

During the year ended December 31, 2018, the Company issued new convertible note in the amount of \$45,000 to an unrelated party. The note bears interest at 8% and is convertible at a 50% discount based on the average of the lowest three closing bid prices over the previous 10 days, with a floor of \$0.000065 per share. In the year ended December 31, 2020, and additional \$3,700 was loaned from the same party under identical terms.

During the year ended December 31, 2021, the Company issued a total of 2,206,600,538 shares of common stock on the conversion of \$267,120 of principal, and \$210,813 in interest and penalties associated with its debt obligations. An additional \$180,458 was recorded as a reduction in derivative liability related to the difference between the value of the shares issued and the amount of principal, interest and penalties recorded based on the value of the common stock on the date of conversion. As of December 31, 2021 and 2020, a total of \$70,303 and \$302,152 in convertible notes payable was outstanding, respectively.

NOTE 4 - EQUITY TRANSACTIONS

Common Stock

The Company has authorized 10 billion shares of common stock, par value \$0.00001, of which 7,831,465,500 shares were issued and outstanding as of December 31, 2021.

During the year ended December 31, 2020, the Company issued the following:

- 300,000,000 shares were issued on the conversion of \$36,000 in interest

In addition, the Company was obligated to issue 31,000,000 shares of common stock resulting from cash sales of \$46,750 and 50,000,000 shares of common stock as consideration for acquiring Cannabis Biosciences, Inc. The value of these shares, \$116,750, was recorded as Stock Payable in the financial statements. On May 1, 2020, Plandai Biotechnology agreed to reduce the amount owing from 50,000,000 shares to 10,000,000 shares and due to breach of contract. As a result, the company reduced the stock payable by \$56,000 which was recorded as other income to offset the write off of the value of the license that was previously impaired.

During the quarter ended March 31, 2021, the Company issued the following:

- 461,330,466 shares were issued to Union Capital on the conversion of \$36,600 in principal and \$55,666 in interest associated with a convertible note payable.
- 468,030,000 shares were issued to BB Winks on the conversion of \$30,500 in principal and \$16,303 in interest associated with a convertible note payable.

During the quarter ended June 30, 2021, the Company issued the following:

- 271,867,306 shares were issued to Union Capital on the conversion of \$63,400 in principal and \$99,720 in interest associated with a convertible note payable.
- 460,000,000 shares were issued to Bruce Lewis on the conversion of \$23,000 in principal and \$23,000 in interest associated with notes payable.
- 400,000,000 shares were issued to Gel Properties, LLC on the conversion of \$45,420 in principal and \$177,561 in interest and penalties associated with a convertible note payable.

During the quarter ended September 30, 2021, the Company issued the following:

- 145,370,766 shares to Lance Quartieri on the conversion of \$25,000 in principal and \$18,611 of interest associated with a convertible note previously issued to CDN Associates.
- 307,258,460 shares issued to Richard Grossfeld on the conversion of 22,151 shares of Series A Preferred Stock.

During the quarter ended December 31, 2021, the Company issued the following:

- 443,290,500 shares to Jaime Safier on the conversion of 30,000 shares of Series A Preferred stock.

Series A Preferred

The Company has 100,000 shares of Series A Preferred stock, par value \$0.001, authorized of which 79,450 shares were issued on December 31st, 2016 in exchange of 504,300 shares of Series B Preferred, previously issued. Of this amount, 10,000, 19,950 and 49,500 Series A were issued to Rock Island, Richard Grossfeld and David Lewis respectively, in exchange for 411,899, 46,052 and 46,052 Series B previously issued and held by each party respectively. The Series A Preferred has conversion rights equal to 20% of the post-conversion issued and outstanding shares of common stock and voting rights equivalent to the total shares issuable on conversion. In the quarter ended September 30, 2021, Richard Grossfeld converted 22,151 shares of Series A Preferred into 307,258,460 shares of common stock. During the quarter ended December 31, 2021, Jaimer Safier converted 46,052 shares of Series B Preferred into 30,000 shares of Series A Preferred. He then converted the 30,000 shares of Series A into 443,290,500 shares of common stock. As of December 31, 2021 and December 31, 2020, there were 49,957 and 72,108 shares of Series A issued and outstanding, respectively.

Series B Preferred

The Company previously issued 550,055 shares of Series B Preferred stock for cash consideration of \$4,825,000. On December 31, 2016, the Company exchanged 504,003 shares of Series B Preferred stock into 79,450 shares of Series A Preferred, leaving 46,052 shares of Series B Preferred stock outstanding as of December 31, 2020. During the quarter ended December 31, 2021, Jaimer Safier converted 46,052 shares of Series B Preferred into 30,000

shares of Series A Preferred. He then converted the 30,000 shares of Series A into 443,290,500 shares of common stock. As of December 31, 2021, there were 457,951 shares of Series B Preferred issued and outstanding. The Series B Preferred has voting rights equal to two votes per share on all shareholder matters and has a preference on dividend payments.

Series C Preferred

The Company has authorized 9,000,000 shares of Series C Preferred stock, par value \$0.001, of which 9,000,000 were previously issued. On December 31, 2016, the holder of 6,325,000 shares of Series C Preferred returned the shares for cancellation in connection with the share exchange with Plandai. The Series C have voting rights equal to 200 votes per share on all shareholder matters.

Series D Preferred

On December 31, 2016, the Company issued 100,000 shares of Series D Preferred stock to acquire 100% of the issued and outstanding capital stock of Plandai Biotechnology South Africa (Pty) Ltd. There are 100,000 shares of Series D Preferred stock, par value \$0.001 authorized, of which 100,000 were outstanding as of December 31, 2019. On May 1, 2020, Plandai cancelled all 100,000 due to breach of contract. The Series D Preferred stock has conversion rights equal to 75% of the post-conversion common stock and voting rights equivalent to the number of shares issuable on conversion.

NOTE 5 – LOSS ON THE WRITE DOWN OF LICENSE

During the year ended December 31, 2019, the Company determined that the license acquired from Plandai Biotechnology to market and sell pharmaceutical products incorporating Plandai's proprietary Phytofare™ extract was materially and permanently impaired due to the failure on the part of Plandai to maintain a sufficient supply of Phytofare™ to enable the Company to conduct the necessary clinical trials and commercialize the product. As a result of this determination, the Company recorded a loss of \$2,000,000 which is recorded in other income and expense in the year ended December 31, 2019. As consideration for Plandai's breach of contract, the Company was entitled to, and received, detailed schematics, technology and know-how enabling the Company to continue the development of products involving the hydrodynamic sheering process of phytonutrient extraction. The Company values this intellectual property at \$170,000, which is recorded as a fixed asset in the accompanying financial statements. On May 1, 2020, Plandai Biotechnology agreed to return 100,000 shares of Series D Preferred stock and reduce the number of shares of common stock owing from the acquisition of Cannabis Biosciences from 50,000,000 to 10,000,000 shares. These transactions resulted from the failure on the part of Plandai to honor certain provisions of the license transfer agreements, including maintaining a sufficient supply of inventory for sales and research, which resulted in the aforementioned impairment. The Company recorded \$56,100 in the year ended December 31, 2020 to offset the previous impairment expense.

NOTE 8 - SUBSEQUENT EVENTS

The Company reviewed transactions subsequent to December 31, 2021 and noted no material events.